Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19260636 | 0.92 | HRH3 (0.56) | HRH3KCNH2ADRA1AKDM4EALDH1A1 | |
| SCHEMBL19260826 | 0.86 | HRH3 (0.51) | HRH3KCNH2ADRA1AKDM4EALDH1A1 | |
| SCHEMBL19260720 | 0.81 | HRH3 (0.54) | HRH3KCNH2ADRA1AKDM4EALDH1A1 | |
| SCHEMBL19260828 | 0.78 | HRH3 (0.54) | HRH3KCNH2ADRA1A | |
| Formic Acid SCHEMBL20720694 | 0.77 | HRH3 (0.52) | HRH3KCNH2ADRA1A | |
| SCHEMBL19260566 | 0.74 | EHMT2 (0.58) | — | |
| Trifluoroacetic Acid SCHEMBL19260686 | 0.74 | KCNH2 (0.43) | HRH3KCNH2ADRA1AKDM4EALDH1A1 | |
| SCHEMBL10809994 | 0.73 | HRH3 (0.64) | HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL20720656 | 0.73 | CACNA2D1 (0.50) | HRH3KCNH2ADRA1AKDM4EALDH1A1 | |
| Formic Acid SCHEMBL19260691 | 0.73 | TLR9 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
| EP-3416963-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017142947-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | HRH3 1038/4885KCNH2 2770/4885ADRA1A 3721/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | HRH3 1038/4885KCNH2 2770/4885ADRA1A 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.